Hsu Shih-Yuan, Wen Zhi-Hong, Shih Po-Chang, Kuo Hsiao-Mei, Lin Sung-Chun, Liu Hsin-Tzu, Lee Yi-Hsin, Wang Yi-Jen, Chen Wu-Fu, Chen Nan-Fu
Department of Marine Biotechnology and Resources, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan.
Department of neurosurgery, Pingtung Christian Hospital, Pingtung 90059, Taiwan.
Antioxidants (Basel). 2022 Jul 23;11(8):1433. doi: 10.3390/antiox11081433.
Glioblastoma multiforme (GBM) is a cancer of largely unknown cause that leads to a 5-year survival rate of approximately 7% in the United States. Current treatment strategies are not effective, indicating a strong need for the development of novel therapies. In this study, the outcomes of sinularin, a marine-derived product, were evaluated against GBM. Our cellular studies using GBM cells revealed that sinularin induces cell death. The measured half maximal inhibitory concentrations (IC) values ranged from 30 to 6 μM at 24-72 h. Cell death was induced via the generation of ROS leading to mitochondria-mediated apoptosis. This was evidenced by annexin V/propidium iodine staining and an upregulation of cleaved forms of the pro-apoptotic proteins caspase 9, 3, and PARP, and supported by CellROX Green, MitoSOX Red, and CM-HDCFDA staining methods. In addition, we observed a downregulation of the antioxidant enzymes SOD1/2 and thioredoxin. Upon treatment with sinularin at the ~IC concentration, mitochondrial respiration capacities were significantly reduced, as shown by measuring the oxygen consumption rates and enzymatic complexes of oxidative phosphorylation. Intriguingly, sinularin significantly inhibited indicators of angiogenesis such as vessel tube formation, cell migration, and cell mobility in human umbilical vein endothelial cells or the fusion cell line EA.Hy926. Lastly, in a transgenic zebrafish model, intersegmental vessel formation was also significantly inhibited by sinularin treatment. These findings indicate that sinularin exerts anti-brain cancer properties that include apoptosis induction but also antiangiogenesis.
多形性胶质母细胞瘤(GBM)是一种病因 largely unknown 的癌症,在美国其5年生存率约为7%。目前的治疗策略无效,这表明迫切需要开发新的治疗方法。在本研究中,评估了一种海洋来源的产品——柳珊瑚素对GBM的治疗效果。我们使用GBM细胞进行的细胞研究表明,柳珊瑚素可诱导细胞死亡。在24至72小时内测得的半数最大抑制浓度(IC)值范围为30至6 μM。细胞死亡是通过活性氧的产生诱导的,导致线粒体介导的凋亡。这通过膜联蛋白V/碘化丙啶染色以及促凋亡蛋白半胱天冬酶9、3和PARP裂解形式的上调得到证实,并得到CellROX Green、MitoSOX Red和CM-HDCFDA染色方法的支持。此外,我们观察到抗氧化酶超氧化物歧化酶1/2和硫氧还蛋白的下调。在用柳珊瑚素以约IC浓度处理后,通过测量氧化磷酸化的氧消耗率和酶复合物,线粒体呼吸能力显著降低。有趣的是,柳珊瑚素显著抑制人脐静脉内皮细胞或融合细胞系EA.Hy926中的血管生成指标,如血管管形成、细胞迁移和细胞运动性。最后,在转基因斑马鱼模型中,柳珊瑚素处理也显著抑制了节间血管形成。这些发现表明,柳珊瑚素具有抗脑癌特性,包括诱导凋亡以及抗血管生成。